This content is for informational purposes only and is not a substitute for professional advice.
Noopept and racetams sit outside ordinary dietary supplement territory in many markets, so the first step is regulatory categories, not dose selection.
Methodology
This page is risk-first education. It does not recommend using noopept, piracetam, phenylpiracetam, oxiracetam, aniracetam, or pramiracetam. We evaluate legal status, product identity risk, medication risk, adverse effects, and whether a trial can be interpreted.
| Risk | Why it matters | Practical response |
|---|---|---|
| Legal status | May not be a lawful supplement ingredient | Check jurisdiction before purchase |
| Quality | Gray-market products can be mislabeled | Avoid products without identity testing |
| Medication risk | CNS effects may interact with drugs | Clinician review |
| Side effects | Anxiety, insomnia, headache, mood change | Stop rules required |
| Attribution | Stacks make effects unreadable | One variable only |
Minimum safety protocol
| Step | Rule |
|---|---|
| Legal check | Confirm local legality and import rules |
| Medical screen | Avoid with seizures, bipolar disorder, pregnancy, psychiatric instability |
| Medication screen | Review stimulants, antidepressants, sedatives, anticoagulants |
| Baseline | 14 days of sleep, mood, anxiety, focus |
| Stop | Agitation, insomnia, chest pain, neurological symptoms, mood elevation |
Decision criteria
If legal status, product identity, or clinician review is unclear, the test should not proceed. For most users, better first trials exist: caffeine plus L-theanine, creatine, sleep correction, or a lower-risk focus protocol.
Sources
This article is educational and does not replace legal or medical advice.
FDA warning letter discussing piracetam supplement claims. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cognitive-nutrition-llc-539376-02052018
↩FTC. Health Products Compliance Guidance. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
↩Pomeroy DE, et al. Supplements and cognitive performance review. https://pmc.ncbi.nlm.nih.gov/articles/PMC7071459/
↩